“…This underscores the fact that many studies have reported highly resistant and have recommended the disbandment of its use as the drug of choice for empirical treatment of UTI management globally. For instance, high rate of resistance against Cotrimoxazole was reported by studies done in India, Brazil, and Iran (Prakash and Saxena, 2013;Jeevan and Zarrin, 2017;Peixoto De Miranda et al, 2014;Rocha et al, 2012;Aghazadeh et al, 2015) and also by other studies done in Ethiopia (Derbie et al, 2017). Nonetheless, reduced susceptibility of E. coli isolates from patients with UTI to Co-trimoxazole varying from (0.00% susceptibility) to (13.90% susceptibility) have been reported by other studies done in different part of Nigeria (Ochada et al, 2014;Oreh and Attama, 2013;Dada-Adegbola and Muili, 2010;Uwaezuoke and Ogbulie, 2006).…”